Gilead Sciences (GILD) : Harvey Capital Management Inc scooped up 2,600 additional shares in Gilead Sciences during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Jul 21, 2016. The investment management firm now holds a total of 123,665 shares of Gilead Sciences which is valued at $10,703,206.Gilead Sciences makes up approximately 5.11% of Harvey Capital Management Inc’s portfolio.
Other Hedge Funds, Including , Equitec Proprietary Markets added GILD to its portfolio by purchasing 1,500 company shares during the most recent quarter which is valued at $129,825. Gilead Sciences makes up approx 0.28% of Equitec Proprietary Markets’s portfolio.Alta Capital Management boosted its stake in GILD in the latest quarter, The investment management firm added 5,905 additional shares and now holds a total of 209,194 shares of Gilead Sciences which is valued at $18,105,741. Gilead Sciences makes up approx 1.08% of Alta Capital Management’s portfolio.Acropolis Investment Management boosted its stake in GILD in the latest quarter, The investment management firm added 965 additional shares and now holds a total of 14,305 shares of Gilead Sciences which is valued at $1,243,534. Gilead Sciences makes up approx 0.23% of Acropolis Investment Management’s portfolio. Nepsis Capital Management sold out all of its stake in GILD during the most recent quarter. The investment firm sold 36,308 shares of GILD which is valued $3,113,411.Forte Capital Adv boosted its stake in GILD in the latest quarter, The investment management firm added 151 additional shares and now holds a total of 49,778 shares of Gilead Sciences which is valued at $4,268,464. Gilead Sciences makes up approx 1.61% of Forte Capital Adv’s portfolio.
Gilead Sciences closed down -0.55 points or -0.67% at $81.24 with 1,29,94,030 shares getting traded on Thursday. Post opening the session at $81.95, the shares hit an intraday low of $80.62 and an intraday high of $81.98 and the price fluctuated in this range throughout the day.Shares ended Thursday session in Red.
On the company’s financial health, Gilead Sciences reported $3.08 EPS for the quarter, beating the analyst consensus estimate by $ 0.07 according to the earnings call on Jul 25, 2016. Analyst had a consensus of $3.01. The company had revenue of $7776.00 million for the quarter, compared to analysts expectations of $7795.08 million. The company’s revenue was down -5.7 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $3.15 EPS.
Many Wall Street Analysts have commented on Gilead Sciences. Shares were Reiterated by RBC Capital Mkts on Jul 26, 2016 to “Outperform” and Lowered the Price Target to $ 105 from a previous price target of $120 .Gilead Sciences was Downgraded by Needham to ” Hold” on Jul 26, 2016. Gabelli & Co Initiated Gilead Sciences on Jun 1, 2016 to “Buy”, Price Target of the shares are set at $109.
Gilead Sciences Inc. (Gilead) is a research-based biopharmaceutical company that discovers develops and commercializes innovative medicines. The Companys primary areas of focus include human immunodeficiency virus (HIV) liver diseases such as chronic hepatitis C virus (HCV) infection and chronic hepatitis B virus (HBV) infection oncology and inflammation and serious cardiovascular and respiratory conditions. The Companys HIV products include Stribild Complera/Eviplera Atripla Truvada Viread Emtriva Tybost and Vitekta. Its Liver Diseases products include Harvoni Sovaldi Viread and Hepsera. Zydelig is the Companys oncology product. Its Cardiovascular products include Letairis Ranexa and Lexiscan/Rapiscan. Its Respiratory products include Cayston and Tamiflu. Its other products include AmBisome and Macugen.